WT1 and acute myeloid leukemia: Paschka et al. [41] analyzed 196 adults aged < 60 years with newly diagnosed primary CN-AML, who were treated similarly with Cancer and Leukemia Group B (CALGB) protocols 9621 and 19808, for WT1 mutations in exons 7 and 9.